|
Status
|
Topic selection
|
|
Technology type
|
Medicine
|
|
Decision
|
Not selected
|
|
Reason for decision
|
Not eligible for Health Technology Evaluation guidance
|
|
Further information
|
The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. The NICE Prioritisation Board (PB) have concluded that the clear rationale to not evaluate this product is due to sulthiame being recommended as a treatment for epilepsy within existing NICE Guideline NG217. The PB acknowledged that the current recommendation is for off label use as third line treatment. However, the board agreed that it would be appropriate to update the guideline following regulatory approval. Therefore, a NICE evaluation is not likely to add any further value to the system.
|
| ID number |
12106
|
Project Team
| Project lead |
Danielle Lees |
Email enquiries
For further information on how we select topics for development, please see our page about prioritising our guidance topics